Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00085306 · ClinicalTrials.gov registry record · Phase 2
Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma
A Phase 2 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT00085306 is a Phase 2 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 21 participants.
The verdict
NCT00085306, a Phase 2 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
RATIONALE: Interferon beta may interfere with the growth of tumor cells. PURPOSE: This phase II trial is studying how well interferon beta works in treating patients with metastatic cutaneous (skin) melanoma or ocular (eye) melanoma.
Interventions
- BIOLOGICAL recombinant interferon beta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2004-04 |
| Est. Completion | 2007-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00085306
The ClinicalTrials.gov registry entry for NCT00085306 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which recombinant interferon beta is the first listed.
NCT00085306 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00085306 about?
NCT00085306 is a clinical study titled "Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma". RATIONALE: Interferon beta may interfere with the growth of tumor cells. PURPOSE: This phase II trial is studying how well interferon beta works in treating patients with metastatic cutaneous (skin) melanoma or ocular (eye) melanoma.
What is the current status of trial NCT00085306?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2004-04. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00085306?
The interventions under investigation include: recombinant interferon beta (BIOLOGICAL).
Who is sponsoring clinical trial NCT00085306?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.